New biweekly diabetes pill could replace daily dosing

NCT ID NCT07198932

Not yet recruiting Disease control Sponsor: Yanbing Li Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will compare two diabetes medications, cofrogliptin and linagliptin, when added to insulin therapy in Chinese adults with type 2 diabetes. About 594 participants will take either a biweekly or daily pill alongside their usual insulin. Researchers will track blood sugar control, side effects, and other health measures over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cofrogliptin and linagliptin
What this could lead to: If successful, this could show that a biweekly pill (cofrogliptin) works as well as a daily pill (linagliptin) for controlling blood sugar in people with type 2 diabetes who already use insulin.
What could go wrong: This is a real-world observational study, not a controlled trial, so results may be less reliable. It is also limited to Chinese adults, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Affiliated Hospital of Hebei University

Baoding, China
Beijing Luhe Hospital Affiliated to Capital Medical University

Beijing, China
Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University

Shanghai, China
Shanghai Changzheng Hospital

Shanghai, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China
Xi'an International Medical Center Hospital

Xi'an, China
the First Medical Center of Chinese PLA General Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.